JP2001503397A - ニューロトロフィンアンタゴニスト組成物 - Google Patents
ニューロトロフィンアンタゴニスト組成物Info
- Publication number
- JP2001503397A JP2001503397A JP51875698A JP51875698A JP2001503397A JP 2001503397 A JP2001503397 A JP 2001503397A JP 51875698 A JP51875698 A JP 51875698A JP 51875698 A JP51875698 A JP 51875698A JP 2001503397 A JP2001503397 A JP 2001503397A
- Authority
- JP
- Japan
- Prior art keywords
- isoquinoline
- dioxo
- lower alkyl
- nitro
- tetrahydrobenzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title claims abstract description 60
- 102000007072 Nerve Growth Factors Human genes 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 239000005557 antagonist Substances 0.000 title description 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 74
- 150000001875 compounds Chemical class 0.000 claims abstract description 57
- -1 benzimidaz-2-yl Chemical group 0.000 claims abstract description 53
- 230000000694 effects Effects 0.000 claims abstract description 28
- 238000001727 in vivo Methods 0.000 claims abstract description 21
- 230000001404 mediated effect Effects 0.000 claims abstract description 19
- 150000002148 esters Chemical class 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 150000001408 amides Chemical class 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 7
- 125000005910 alkyl carbonate group Chemical group 0.000 claims abstract description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract description 6
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
- 125000001769 aryl amino group Chemical group 0.000 claims abstract description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 4
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 5
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 76
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 claims description 28
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 210000002569 neuron Anatomy 0.000 claims description 14
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- BSMLNRFWSYKIEP-UHFFFAOYSA-N 2-(dimethylamino)-5-nitro-4,4a-dihydrobenzo[i]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC=C2C=CC=CC32C1CC(=O)N(N(C)C)C3=O BSMLNRFWSYKIEP-UHFFFAOYSA-N 0.000 claims description 7
- XNPLAGSBSNNWSD-UHFFFAOYSA-N (1,3-dioxo-4,4a-dihydrobenzo[i]isoquinolin-2-yl) acetate Chemical compound C1=CC=C2C=CC=CC32C1CC(=O)N(OC(=O)C)C3=O XNPLAGSBSNNWSD-UHFFFAOYSA-N 0.000 claims description 6
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 6
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 239000011574 phosphorus Substances 0.000 claims description 6
- LIMGTTOBSVFWHF-UHFFFAOYSA-N 6-phenylsulfanyl-2-(2-pyridin-2-ylethyl)-4,4a-dihydrobenzo[i]isoquinoline-1,3-dione Chemical compound C1=C2C=CC=CC32C(=O)N(CCC=2N=CC=CC=2)C(=O)CC3C=C1SC1=CC=CC=C1 LIMGTTOBSVFWHF-UHFFFAOYSA-N 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- XQFSDWLIFRTQQP-UHFFFAOYSA-N 6-bromo-2-(dimethylamino)-4,4a-dihydrobenzo[i]isoquinoline-1,3-dione Chemical compound C1=C(Br)C=C2C=CC=CC32C1CC(=O)N(N(C)C)C3=O XQFSDWLIFRTQQP-UHFFFAOYSA-N 0.000 claims description 2
- UUIQMZJEGPQKFD-UHFFFAOYSA-N Methyl butyrate Chemical compound CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 claims description 2
- 229910000071 diazene Inorganic materials 0.000 claims description 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 2
- 230000012010 growth Effects 0.000 abstract description 8
- 230000003376 axonal effect Effects 0.000 abstract description 4
- 230000004770 neurodegeneration Effects 0.000 abstract description 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 2
- 229940053128 nerve growth factor Drugs 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 241000700159 Rattus Species 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 208000004454 Hyperalgesia Diseases 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 6
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 6
- 108090000099 Neurotrophin-4 Proteins 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000004031 neuronal differentiation Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
- 102000003683 Neurotrophin-4 Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 229940097998 neurotrophin 4 Drugs 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 210000003594 spinal ganglia Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100029268 Neurotrophin-3 Human genes 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 108090000095 Neurotrophin-6 Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 239000003855 balanced salt solution Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000020341 sensory perception of pain Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 101150111783 NTRK1 gene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 210000000609 ganglia Anatomy 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000006576 neuronal survival Effects 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 102000015533 trkA Receptor Human genes 0.000 description 2
- 108010064884 trkA Receptor Proteins 0.000 description 2
- 102000015534 trkB Receptor Human genes 0.000 description 2
- 108010064880 trkB Receptor Proteins 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- DYWWDZQRZYAPHQ-UHFFFAOYSA-N 3-benzoyl-4-ethyl-4-methyl-2-phenyl-1,3-oxazolidin-5-one Chemical compound O1C(=O)C(CC)(C)N(C(=O)C=2C=CC=CC=2)C1C1=CC=CC=C1 DYWWDZQRZYAPHQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000451147 Lacon Species 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102100033857 Neurotrophin-4 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 101150084935 PTER gene Proteins 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012913 medium supplement Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229940032018 neurotrophin 3 Drugs 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 102000047459 trkC Receptor Human genes 0.000 description 1
- 108010064892 trkC Receptor Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. ニューロトロフィン介在活性を阻害するのに有効な量で、式I: {式中、R1は、アルキル;アリール−低級アルキル;複素環−低級アルキル; 低級アルキル−カーボネート;低級アルキル、アリールおよびヒドロキシ低級ア ルキルから選ばれた置換基で任意にモノ置換またはジ置換されたアミノ;ベンズ イミダズ−2−イル; 〔式中、R4は、低級アルキルおよびハロから選ばれた置換基で任意にモノ置換 またはジ置換されたフェニル;アミノ、低級アルコキシ、ヒドロキシおよび低級 アルキルから選ばれた置換基で任意にモノ置換またはジ置換されたフェニル;N HCH2CH2OX(ここで、Xは、イン・ビボで加水分解可能なエステルを示す );および低級アルキル−(R5)(R6)(ここで、R5およびR6の一方は、H および低級アルキルから選ばれたものであり、他方は、カルボキシ、カル ボキシ−低級アルキルおよび低級アルコキシカルボニルから選ばれたものである )である〕から選ばれたものであり;ならびに R2およびR3は、H、NO2、ハロ、ジ(低級アルキル)アミノ、シアノ、C( O)OH、フェニル−S−、低級アルキルおよびZ(O)OR7(ここで、Zは 、CおよびSから選ばれたものであり、R7は、H、低級アルキルアミノおよび アリールアミノから選ばれたものである)から独立に選ばれたものである}の化 合物; ならびにそれらの製薬上許容されうる塩、ならびに適当な担体を含有してなる医 薬組成物。 2. R1がアルキル;アリール−低級アルキル;複素環−低級アルキル;低級 アルキル−カーボネート;低級アルキルおよびヒドロキシ低級アルキルから選ば れた置換基で任意にモノ置換またはジ置換されたアミノ;ベンズイミダズ−2− イル; 〔式中、R4は、低級アルキルおよびハロから選ばれた置換基で任意にモノ置換 またはジ置換されたフェニル;アミノ、低級アルコキシ、ヒドロキシおよび低級 アルキルから選ばれた置換基で任意にモノ置換またはジ置換されたフェニル;N HCH2CH2OX(ここで、Xは、イン・ビボで加水分解可能なエステルを示す );および低級アルキル−(R5)(R6)(ここで、R5およびR6の一方 は、Hおよび低級アルキルから選ばれたものであり、他方は、カルボキシ、カル ボキシ−低級アルキルおよび低級アルコキシ−カルボニルから選ばれたものであ る)である〕から選ばれたものであり;ならびに R2およびR3が、H、NO2、ハロ、ジ(低級アルキル)アミノおよびフェニル −S−から独立に選ばれたものである請求項1記載の医薬組成物。 3. R1がアリール−低級アルキル;複素環−低級アルキル;低級アルキル− カーボネート;低級アルキルおよびヒドロキシ低級アルキルから選ばれた置換基 で任意にモノ置換またはジ置換されたアミノ;ベンズイミダズ−2−イル;NH CH2CH2OX(ここで、Xは、イン・ビボで加水分解可能なエステルを示す) ;および低級アルキル−(R5)(R6)(ここで、R5およびR6の一方は、Hお よび低級アルキルから選ばれたものであり、他方は、カルボキシ、カルボキシ− 低級アルキルおよび低級アルコキシ−カルボニルから選ばれたものである)から 選ばれたものであり;ならびに R2およびR3が、H、NO2、ジ(低級アルキル)アミノおよびフェニル−S− から独立に選ばれたものである請求項2記載の医薬組成物。 4. R1が低級アルキルおよびヒドロキシ低級アルキルから選ばれた置換基で 任意にモノ置換またはジ置換されたアミノ;NHCH2CH2OX(ここで、Xは 、イン・ビボで加水分解可能なエステルを示す);および低級アルキル−(R5 )(R6)(ここで、R5およびR6の一方は、Hおよび低級アルキルから選ばれ たものであり、他方は、カルボキシ、カルボキシ−低級アルキルおよび低級アル コキシ−カルボニルから選ばれたものである)から選ばれたものであり;ならび に R2およびR3が、HおよびNO2から独立に選ばれたものである請求項3記載の 医薬組成物。 5. 式Iの化合物が: N−{5−ニトロ−1H−ベンズ[de]イソキノリン−1,3(2H)−ジオ ン}−2−アミノエタノール; N−ジメチルアミノ−1,3−ジオキソ−5−ニトロ−1,2,3,4−テトラ ヒドロベンゾ[i]イソキノリン; N−(1,3−ジオキソ−5−ニトロ−1,2,3,4−テトラヒドロベンゾ[ i]イソキノリン)酢酸; N−アセトキシ−1,3−ジオキソ−1,2,3,4−テトラヒドロベンゾ[i ]イソキノリン; N−(1,3−ジオキソ−5−ニトロ−1,2,3,4−テトラヒドロベンゾ[ i]イソキノリン)アミノエタノール; N−フルフリル−1,8−ナフタルイミド; 6−(N,N−ジメチルアミノ)−2−(ベンズイミダゾール−2−イル)ナフ タルイミド; N−(ピリド−2−イルエチル)−1,8−ナフタルイミド; 1,3−ジオキソ−6−フェニルメルカプト−N−(ピリド−2−イルエチル) −1,2,3,4−テトラヒドロベンゾ[i]イソキノリン; 2−{2−(4−メチルフェニルスルホンアミド)フェニル}−6−(N,N− ジメチルアミノ)ナフタルイミド; 1,3−ジオキソ−2−{2−(4−メチルフェニルスルホンアミド)フェニル }−1,2,3,4−テトラヒドロベンゾ[i]イソキノリン; N−オクチル−5−ニトロナフタルイミド; 5−ブロモ−1,3−ジオキソ−N−メチルピリド−3−イル−1,2,3,4 −テトラヒドロベンゾ[i]イソキノリン; 1,3−ジオキソ−5−ニトロ−N−(ピリド−2−イルエチル)−1,2,3 ,4−テトラヒドロ[i]イソキノリン; 6−ニトロ−2−(テトラヒドロフラン−2−イルメチル)ナフタルイミド; N−(1,3−ジオキソ−1,2,3,4−テトラヒドロベンゾ[i]イソキノ リン)アミノエタノール; ナフタル酸−N−アミノイミド; 2−{2−(4−メチルベンズスルホンアミド)−4,5−ジクロロフェニル} ナフタルイミド; 3−ニトロ−1,8−(N−プロピオンカルボキシレート)スクシンアミドナフ タリン; 1,3−ジオキソ−2−(2−アミノフェニル)−1,2,3,4−テトラヒド ロベンゾ[i]イソキノリン; 6−ニトロ−2−(ピリド−3−メチル)ナフタルイミド; 3−アミノ−7,4−ビス(エチル−1,3−ジオキソ)−1,2,3,4−テ トラヒドロベンゾ[i]イソキノリン; 2−(ベンズイミダズ−2−イル)−1,3−ジオキソ−1,2,3,4−テト ラヒドロベンゾ[i]イソキノリン; 2−(2−アミノフェニル)ナフタルイミド; 1,3−ジオキソ−2−{4,5−ジメチル−2−(4−メチルフェニルスルホ ンアミド)フェニル}−1,2,3,4−テトラヒドロベンゾ[i]イソキノリ ン; 3−メチル−3−(1,3−ジオキソ−5−ニトロ(1H,3H)ベンズ[de ]イソキノリル)酪酸メチルエステル; 1,3−ジオキソ−N−メチルテトラヒドロフルフル−2−イル−5−ニトロ− 1,2,3,4−テトラヒドロ[i]イソキノリン; N−(4−エトキシフェニル)−5−ニトロナフタルイミド; 6−ニトロ−2−(フルフリル)ナフタルイミド; エチル−5−ニトロ−1,3−ジオキソ−1H−ベンズ[de]イソキノリン− 2−3H−アセテート; ナフタル酸−N,N’−ジイミド; 2−(2−ヒドロキシフェニル)ナフタルイミド; 5−アミノ−N−ブチルナフタルイミド; 1,3−ジオキソ−5−ニトロ−n−プロピルモルホリノ−1,2,3,4−テ トラヒドロベンゾ[i]イソキノリン; 6−ニトロ−2−(ピリド−2−イルエチル)ナフタルイミド; N−メチルナフタルイミド; N−(ピリド−2−イルメチル)ナフタルイミド; N−(3,5−ジメチルフェニル)−1,8−ナフタルイミド; 6−ブロモ−N−ジメチルアミノ−1,3−ジオキソ−1,2,3,4−テトラ ヒドロベンゾ[i]イソキノリン; N−(1,3−ジオキソ−6−フェニルメルカプト−1,2,3,4−テトラヒ ドロベンゾ[i]イソキノリン)アミノエタノール;および N−アニリノ−1,8−ナフタルイミドからなる群より選ばれたものである請求 項1記載の医薬組成物。 6. 式Iの化合物が: N−{5−ニトロ−1H−ベンズ[de]イソキノリン−1,3(2H)−ジオ ン}−2−アミノエタノール; N−ジメチルアミノ−1,3−ジオキソ−5−ニトロ−1,2,3,4−テトラ ヒドロベンゾ[i]イソキノリン; N−(1,3−ジオキソ−5−ニトロ−1,2,3,4−テトラヒドロベンゾ[ i]イソキノリン)酢酸; N−アセトキシ−1,3−ジオキソ−1,2,3,4−テトラヒドロベンゾ[i ]イソキノリン; N−(1,3−ジオキソ−5−ニトロ−1,2,3,4−テトラヒドロベンゾ[ i]イソキノリン)アミノエタノール; N−フルフリル−1,8−ナフタルイミド; 6−(N,N−ジメチルアミノ)−2−(ベンズイミダゾール−2−イル)ナフ タルイミド; N−(ピリド−2−イルエチル)−1,8−ナフタルイミド; 1,3−ジオキソ−6−フェニルメルカプト−N−(ピリド−2−イルエチル) −1,2,3,4−テトラヒドロベンゾ[i]イソキノリン; 2−{2−(4−メチルフェニルスルホンアミド)フェニル}−6−(N,N− ジメチルアミノ)ナフタルイミド; 1,3−ジオキソ−2−{2−(4−メチルフェニルスルホンアミド)フェニル }−1,2,3,4−テトラヒドロベンゾ[i]イソキノリン; N−オクチル−5−ニトロナフタルイミド; 5−ブロモ−1,3−ジオキソ−N−メチルピリド−3−イル−1,2,3,4 −テトラヒドロベンゾ[i]イソキノリン; 1,3−ジオキソ−5−ニトロ−N−(ピリド−2−イルエチル)−1,2,3 ,4−テトラヒドロ[i]イソキノリン; 6−ニトロ−2−(テトラヒドロフラン−2−イルメチル)ナフタルイミド; N−(1,3−ジオキソ−1,2,3,4−テトラヒドロベンゾ[i]イソキノ リン)アミノエタノール; ナフタル酸−N−アミノイミド; 2−{2−(4−メチルベンズスルホンアミド)−4,5−ジクロロフェニル} ナフタルイミド; 3−ニトロ−1,8−(N−プロピオンカルボキシレート)スクシンアミドナフ タリン; 1,3−ジオキソ−2−(2−アミノフェニル)−1,2,3,4−テトラヒド ロベンゾ[i]イソキノリン; 6−ニトロ−2−(ピリド−3−メチル)ナフタルイミド; 3−アミノ−7,4−ビス(エチル−1,3−ジオキソ−1,2,3,4−テト ラヒドロベンゾ[i]イソキノリン; 2−(ベンズイミダズ−2−イル)−1,3−ジオキソ−1,2,3,4−テト ラヒドロベンゾ[i]イソキノリン;および 2−(2−アミノフェニル)ナフタルイミドからなる群より選ばれたものである 請求項2記載の医薬組成物。 7. 式Iの化合物が: N−{5−ニトロ−1H−ベンズ[de]イソキノリン−1,3(2H)−ジオ ン}−2−アミノエタノール; N−ジメチルアミノ−1,3−ジオキソ−5−ニトロ−1,2,3,4−テトラ ヒドロベンゾ[i]イソキノリン; N−(1,3−ジオキソ−5−ニトロ−1,2,3,4−テトラヒドロベンゾ[ i]イソキノリン)酢酸; N−アセトキシ−1,3−ジオキソ−1,2,3,4−テトラヒドロベンゾ[i ]イソキノリン; N−(1,3−ジオキソ−5−ニトロ−1,2,3,4−テトラヒドロベンゾ[ i]イソキノリン)アミノエタノール; N−フルフリル−1,8−ナフタルイミド; 6−(N,N−ジメチルアミノ)−2−(ベンズイミダゾール−2−イル)ナフ タルイミド; N−(ピリド−2−イルエチル)−1,8−ナフタルイミド;および 1,3−ジオキソ−6−フェニルメルカプト−N−(ピリド−2−イルエチル) −1,2,3,4−テトラヒドロベンゾ[i]イソキノリンからなる群より選ば れたものである請求項3記載の医薬組成物。 8. 式Iの化合物が: N−{5−ニトロ−1H−ベンズ[de]イソキノリン−1,3(2H)−ジオ ン}−2−アミノエタノール; N−ジメチルアミノ−1,3−ジオキソ−5−ニトロ−1,2,3,4−テトラ ヒドロベンゾ[i]イソキノリン; N−(1,3−ジオキソ−5−ニトロ−1,2,3,4−テトラヒドロベンゾ[ i]イソキノリン)酢酸; N−アセトキシ−1,3−ジオキソ−1,2,3,4−テトラヒドロベンゾ[i ]イソキノリン;および N−(1,3−ジオキソ−5−ニトロ−1,2,3,4−テトラヒドロベンゾ[ i]イソキノリン)アミノエタノールからなる群より選ばれたものである請求項 4記載の医薬組成物。 9. NGF介在活性を阻害する請求項1記載の医薬組成物。 10. 有効量の請求項1記載の組成物にニューロン細胞を曝す工程を含む、ニ ューロトロフィン介在活性を阻害する方法。 11. 治療上有効量の請求項1記載の組成物を哺乳動物に投与する工程を含む 、哺乳動物におけるニューロトロフィン介在活性を阻害する方法。 12. 前記組成物が脳室内に投与される請求項11記載の方法。 13. N−{5−ニトロ−1H−ベンズ[de]イソキノリン−1,3(2H )−ジオン}−2−アミノエタノール; N−(1,3−ジオキソ−5−ニトロ−1,2,3,4−テトラヒドロベンゾ[ i]イソキノリン)酢酸; N−(1,3−ジオキソ−5−ニトロ−1,2,3,4−テトラヒドロベンゾ[ i]イソキノリン)アミノエタノール; N−(1,3−ジオキソ−1,2,3,4−テトラヒドロベンゾ[i]イソキノ リン)アミノエタノール; ナフタル酸−N−アミノイミド; 3−ニトロ−1,8−(N−プロピオンカルボキシレート)スクシンアミドナフ タリン; 1,3−ジオキソ−2−(2−アミノフェニル)−1,2,3,4−テトラヒド ロベンゾ[i]イソキノリン; 3−アミノ−7,4−ビス(エチル−1,3−ジオキソ)−1,2,3,4−テ トラヒドロベンゾ[i]イソキノリン; 2−(2−アミノフェニル)ナフタルイミド;および 2−(2−ヒドロキシフェニル)ナフタルイミドからなる群より選ばれた化合物 のイン・ビボで加水分解可能なエステルまたはアミド。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9621902.7 | 1996-10-21 | ||
GBGB9621902.7A GB9621902D0 (en) | 1996-10-21 | 1996-10-21 | Neurotrophin antagonist compositions |
GBGB9710904.5A GB9710904D0 (en) | 1997-05-27 | 1997-05-27 | Neurotropin antagonist compositions |
GB9710904.5 | 1997-05-27 | ||
PCT/CA1997/000779 WO1998017278A1 (en) | 1996-10-21 | 1997-10-20 | Neurotrophin antagonist compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001503397A true JP2001503397A (ja) | 2001-03-13 |
JP2001503397A5 JP2001503397A5 (ja) | 2005-06-16 |
Family
ID=26310264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51875698A Ceased JP2001503397A (ja) | 1996-10-21 | 1997-10-20 | ニューロトロフィンアンタゴニスト組成物 |
Country Status (14)
Country | Link |
---|---|
US (4) | US20020169182A1 (ja) |
EP (1) | EP0930883B1 (ja) |
JP (1) | JP2001503397A (ja) |
KR (1) | KR20000052691A (ja) |
AT (1) | ATE315397T1 (ja) |
AU (1) | AU728523C (ja) |
BR (1) | BR9712424A (ja) |
CA (1) | CA2268450C (ja) |
DE (1) | DE69735090T2 (ja) |
DK (1) | DK0930883T3 (ja) |
ES (1) | ES2257768T3 (ja) |
IL (1) | IL129475A0 (ja) |
NZ (1) | NZ335291A (ja) |
WO (1) | WO1998017278A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007512384A (ja) * | 2003-12-01 | 2007-05-17 | サノフイ−アベンテイス | 4−[(アリールメチル)アミノメチル]ピペリジン誘導体、これらの調製、および治療におけるこれらの適用 |
JP2007512385A (ja) * | 2003-12-01 | 2007-05-17 | サノフイ−アベンテイス | (4−フェニルピペラジン−1−イル)アシルピペリジン誘導体、これらの調製、および治療におけるこれらの適用 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE315397T1 (de) | 1996-10-21 | 2006-02-15 | Allelix Biopharma | Neurotrophin antagoniste zur behandlung von der epilepsie, alzheimer'schen krankheit und schmerzen |
ID29425A (id) * | 1998-11-25 | 2001-08-30 | Merck Patent Gmbh | BENZO (dE) ISOQUINOLIN-1,3-DIONE TERSUBSTITUSI |
AU760136B2 (en) * | 1998-11-25 | 2003-05-08 | Merck Patent Gmbh | Substituted benzo(DE)isoquinoline-1,3-diones |
US6468990B1 (en) * | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
US6492380B1 (en) * | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
ATE497391T1 (de) | 2002-10-08 | 2011-02-15 | Rinat Neuroscience Corp | Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
ZA200504866B (en) | 2002-12-24 | 2006-11-29 | Rinat Neuroscience Corp | Anti-ngf antibodies and methods using same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
CA2516454A1 (en) | 2003-02-19 | 2004-09-02 | Rinat Neuroscience Corp. | Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
KR20060135060A (ko) | 2004-04-07 | 2006-12-28 | 리나트 뉴로사이언스 코퍼레이션 | 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법 |
GB0419850D0 (en) * | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
CA2622571A1 (en) * | 2005-09-15 | 2007-03-22 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
US20090082368A1 (en) * | 2007-09-24 | 2009-03-26 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
FR2953839A1 (fr) * | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
RS63063B1 (sr) | 2010-08-19 | 2022-04-29 | Zoetis Belgium S A | Anti-ngf antitela i njihova upotreba |
EP2606894A1 (en) | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
CN104364264B (zh) | 2012-06-06 | 2018-07-24 | 硕腾服务有限责任公司 | 犬源化抗ngf抗体和其方法 |
EP3765499A1 (en) | 2018-03-12 | 2021-01-20 | Zoetis Services LLC | Anti-ngf antibodies and methods thereof |
WO2023212596A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US627129A (en) * | 1899-06-20 | Collar-edge-ironing machine | ||
US525841A (en) * | 1894-09-11 | Baling-press | ||
US3821383A (en) * | 1972-07-10 | 1974-06-28 | Ayerst Mckenna & Harrison | Compositions for and a method of treating diabetic complications |
US4006238A (en) | 1975-08-28 | 1977-02-01 | E. R. Squibb & Sons, Inc. | Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents |
ES459497A1 (es) | 1977-06-04 | 1978-04-16 | Made Labor Sa | Un metodo para la preparacion industrial de naftalimidas y sus derivados. |
US4254109A (en) * | 1979-11-08 | 1981-03-03 | Ayerst, Mckenna & Harrison Inc. | 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives |
RU2051677C1 (ru) * | 1982-02-10 | 1996-01-10 | Украинский научно-исследовательский институт эндокринологии и обмена веществ | Средство для профилактики и лечения диабетических осложнений, ангиопатий, нейропатий, катаракты |
US5183821A (en) | 1983-09-19 | 1993-02-02 | Laboratories Knoll, S.A. | Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors |
IT1214618B (it) * | 1985-06-27 | 1990-01-18 | I P A International Pharmaceut | Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche. |
DE3635711A1 (de) | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
DE3707651A1 (de) | 1987-03-10 | 1988-09-22 | Knoll Ag | Bis-naphthalimide, ihre herstellung und verwendung |
DE3707652A1 (de) * | 1987-03-10 | 1988-09-22 | Knoll Ag | Verwendung von benzo(de)isochinolin-1,3-dionen zur herstellung von arzneimitteln |
US5420137A (en) | 1989-07-11 | 1995-05-30 | Knoll Ag | Amonafide salts |
US5356906A (en) * | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
CA2030129A1 (en) | 1989-11-29 | 1991-05-30 | Thomas Saupe | 1,8-napthalenedicarboximides as antidotes |
US5342942A (en) | 1992-06-09 | 1994-08-30 | Warner-Lambert Company | Pyrazoloquinazolone derivatives as neurotrophic agents |
DE4232739A1 (de) | 1992-09-30 | 1994-03-31 | Knoll Ag | Neue asymmetrisch substituierte bis-Naphthalimide |
IL110460A (en) | 1993-08-18 | 2001-01-11 | Basf Ag | Bite-naphthalimides, their preparation and pharmaceutical preparations containing them |
US6291247B1 (en) | 1994-05-11 | 2001-09-18 | Queen's University At Kingston | Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity |
GB9616105D0 (en) | 1996-07-31 | 1996-09-11 | Univ Kingston | TrkA binding site of NGF |
ATE315397T1 (de) | 1996-10-21 | 2006-02-15 | Allelix Biopharma | Neurotrophin antagoniste zur behandlung von der epilepsie, alzheimer'schen krankheit und schmerzen |
EP1015008B1 (en) | 1997-02-07 | 2015-08-05 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
WO1998052919A1 (fr) | 1997-05-21 | 1998-11-26 | Japan Tobacco Inc. | Derives de phtalimide et produit pharmaceutique contenant ces derives |
WO2000000472A1 (en) | 1998-06-30 | 2000-01-06 | Du Pont Pharmaceuticals Company | 5-ht7 receptor antagonists |
JP3357662B2 (ja) | 1998-07-03 | 2002-12-16 | 大鵬薬品工業株式会社 | ナフタルイミドベンズアミド誘導体 |
US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
-
1997
- 1997-10-20 AT AT97909098T patent/ATE315397T1/de not_active IP Right Cessation
- 1997-10-20 EP EP97909098A patent/EP0930883B1/en not_active Expired - Lifetime
- 1997-10-20 BR BR9712424-9A patent/BR9712424A/pt not_active Application Discontinuation
- 1997-10-20 DK DK97909098T patent/DK0930883T3/da active
- 1997-10-20 NZ NZ335291A patent/NZ335291A/en unknown
- 1997-10-20 DE DE69735090T patent/DE69735090T2/de not_active Expired - Fee Related
- 1997-10-20 CA CA002268450A patent/CA2268450C/en not_active Expired - Fee Related
- 1997-10-20 JP JP51875698A patent/JP2001503397A/ja not_active Ceased
- 1997-10-20 AU AU46968/97A patent/AU728523C/en not_active Ceased
- 1997-10-20 IL IL12947597A patent/IL129475A0/xx not_active IP Right Cessation
- 1997-10-20 KR KR1019990703479A patent/KR20000052691A/ko not_active Application Discontinuation
- 1997-10-20 ES ES97909098T patent/ES2257768T3/es not_active Expired - Lifetime
- 1997-10-20 WO PCT/CA1997/000779 patent/WO1998017278A1/en active IP Right Grant
-
2001
- 2001-01-11 US US09/758,917 patent/US20020169182A1/en not_active Abandoned
-
2005
- 2005-07-13 US US11/179,610 patent/US7291629B2/en not_active Expired - Fee Related
-
2007
- 2007-09-28 US US11/905,406 patent/US20080287484A1/en not_active Abandoned
-
2009
- 2009-04-28 US US12/453,032 patent/US20090215815A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007512384A (ja) * | 2003-12-01 | 2007-05-17 | サノフイ−アベンテイス | 4−[(アリールメチル)アミノメチル]ピペリジン誘導体、これらの調製、および治療におけるこれらの適用 |
JP2007512385A (ja) * | 2003-12-01 | 2007-05-17 | サノフイ−アベンテイス | (4−フェニルピペラジン−1−イル)アシルピペリジン誘導体、これらの調製、および治療におけるこれらの適用 |
JP4668924B2 (ja) * | 2003-12-01 | 2011-04-13 | サノフイ−アベンテイス | 4−[(アリールメチル)アミノメチル]ピペリジン誘導体、これらの調製、および治療におけるこれらの適用 |
JP4669479B2 (ja) * | 2003-12-01 | 2011-04-13 | サノフイ−アベンテイス | (4−フェニルピペラジン−1−イル)アシルピペリジン誘導体、これらの調製、および治療におけるこれらの適用 |
Also Published As
Publication number | Publication date |
---|---|
CA2268450C (en) | 2008-08-05 |
US20080287484A1 (en) | 2008-11-20 |
NZ335291A (en) | 2001-02-23 |
US7291629B2 (en) | 2007-11-06 |
US20090215815A1 (en) | 2009-08-27 |
US20050250807A1 (en) | 2005-11-10 |
BR9712424A (pt) | 2001-11-20 |
AU728523B2 (en) | 2001-01-11 |
IL129475A0 (en) | 2000-02-29 |
AU728523C (en) | 2001-08-09 |
DE69735090T2 (de) | 2006-09-14 |
WO1998017278A1 (en) | 1998-04-30 |
EP0930883B1 (en) | 2006-01-11 |
KR20000052691A (ko) | 2000-08-25 |
ATE315397T1 (de) | 2006-02-15 |
ES2257768T3 (es) | 2006-08-01 |
DE69735090D1 (de) | 2006-04-06 |
AU4696897A (en) | 1998-05-15 |
EP0930883A1 (en) | 1999-07-28 |
DK0930883T3 (da) | 2006-05-22 |
US20020169182A1 (en) | 2002-11-14 |
CA2268450A1 (en) | 1998-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001503397A (ja) | ニューロトロフィンアンタゴニスト組成物 | |
JP3943126B2 (ja) | ニューロトロフィン誘導活性を高めるK−252a誘導体 | |
US6492380B1 (en) | Method of inhibiting neurotrophin-receptor binding | |
JP2002515072A (ja) | Parpインヒビター、当該インヒビターを含む薬学的組成物および当該インヒビターの使用方法 | |
JP2002515490A (ja) | Parp活性を抑制する縮合三環化合物 | |
WO1994022866A1 (en) | Pyrazoloquinazolone derivatives as neurotrophic agents | |
IL128877A (en) | High-specific butyrilcholinesterase inhibitors for the prevention and treatment of cognitive impairments associated with aging or Alzheimer's disease and new compounds of this kind | |
EP2985283A1 (en) | Anti-angiogenesis compound, intermediate and use thereof | |
JP2007529555A (ja) | シヌクレイノパチーを治療する方法 | |
US5075305A (en) | Compound, composition and use | |
CN113698345B (zh) | 作为钾通道调节剂的化合物及其制备和应用 | |
KR20080093453A (ko) | 4-아실아미노피리딘 유도체 매개된 신경조직발생 | |
JP3464230B2 (ja) | ピリダジンジオン化合物、該化合物を含有する神経障害を治療するための医薬組成物、動物の神経障害を治療する方法、及び該化合物の製造方法 | |
EP3233895A1 (en) | Anti-arrhythmicity agents | |
JPH10512269A (ja) | 大脳の変性疾患の治療または予防用の医薬組成物の製造のための3,4−ジフェニルクロマンの使用 | |
US5434177A (en) | Imidazoles for the treatment of age-related cognitive disorders and alzheimer | |
WO2023143388A1 (zh) | 作为钾通道调节剂的酰胺类化合物及其制备和应用 | |
Mocchetti | Theoretical basis for a pharmacology of nerve growth factor biosynthesis | |
US5580877A (en) | Pyrazolo-quinoline derivatives for treating cerebral ischemia | |
EA011255B1 (ru) | Производные 2-аминобензойной кислоты | |
US5098902A (en) | Method of treating neurodegenerative diseases | |
MXPA99003637A (es) | Composiciones antagonistas de las neurotrofinas | |
RU2799454C2 (ru) | Терапевтический препарат для лечения нейродегенеративных заболеваний и его применение | |
JP2820698B2 (ja) | 脳機能改善剤 | |
JP2001002572A (ja) | ニューロトロフィン作用増強剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041019 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041019 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080708 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081002 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081030 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081208 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081203 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090119 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090217 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090609 |